

Global Vaccine Adjuvants Market - 2025 -2033

<https://marketpublishers.com/r/G0848AFC1466EN.html>

Date: October 2025

Pages: 180

Price: US\$ 4,350.00 (Single User License)

ID: G0848AFC1466EN

Abstracts

Vaccine Adjuvants Market Size & Industry Outlook

The global vaccine adjuvants market size reached US\$ 703.15 Million in 2024 from US\$ 661.09 Million in 2023 and is expected to reach US\$ 1,280.35 Million by 2033, growing at a CAGR of 6.9% during the forecast period 2025-2033. The market is evolving as a critical enabler of next-generation vaccines, driven by the need to enhance immunogenicity in subunit, recombinant, and emerging mRNA platforms. Traditional mineral salts such as alum remain widely used in pediatric and adult prophylactic vaccines, while advanced systems like MF59, AS03, and AS01 have gained prominence in influenza, shingles, and malaria programs.

Recent approvals, such as CpG 1018 in hepatitis B vaccines, highlight the growing role of TLR agonists in commercial products. Demand is also fueled by oncology and therapeutic vaccine research, where potent adjuvant systems like QS-21 and liposome-based formulations are being tested. North America currently leads adoption due to established vaccine pipelines and regulatory approvals, but emerging markets like APAC are gaining traction through local production and government immunization drives.

Key Market Trends & Insights

Key trends in the vaccine adjuvants market reflect a shift from conventional alum-based systems toward more sophisticated adjuvant platforms that can enhance targeted immune responses. Oil-in-water emulsions such as MF59 and AS03 are increasingly used in seasonal and pandemic influenza vaccines, while liposome-based systems like AS01, used in GSK's Shingrix and malaria vaccine Mosquirix, set benchmarks for efficacy in older adults and complex pathogens. TLR agonists, exemplified by Dynavax's CpG 1018 in hepatitis B

vaccines, demonstrate the rising acceptance of nucleic acid-based adjuvants in licensed products.

The integration of adjuvants with mRNA and protein subunit platforms, particularly highlighted during COVID-19 vaccine development. Oncology and therapeutic vaccine pipelines are also accelerating demand for potent adjuvants like QS-21 and novel nanoparticles.

North America dominates the vaccine adjuvants market with the largest revenue share of 44.02% in 2024.

The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of 6.8% over the forecast period.

Based on application, the infectious diseases segment led the market with the largest revenue share of 49.87% in 2024.

The major market players in the vaccine adjuvants market are GSK, Dynavax Technologies, Novavax, SPI Pharma, Agenus Inc., CSL, InvivoGen, Brenntag Nicaragua, S.A., and OZ Biosciences, among others

Market Size & Forecast

2024 Market Size: US\$ 703.15 Million

2033 Projected Market Size: US\$ 1,280.35 Million

CAGR (2025–2033): 6.9%

North America: Largest market in 2024

Asia Pacific: Fastest-growing market

Market Dynamics

Drivers-The rising threat of emerging infectious diseases and pandemics is significantly driving the vaccine adjuvants market growth

The rising threat of emerging infectious diseases and pandemics is increasingly shaping the vaccine adjuvants market, as global health systems seek technologies that can both accelerate vaccine development and extend protection in high-risk populations. Unlike traditional live or inactivated vaccines, many modern platforms such as protein subunit, recombinant, and mRNA vaccines often produce weaker immune responses and therefore depend on adjuvants to boost efficacy. This became especially evident during the 2009 H1N1 influenza pandemic, when AS03-adjuvanted vaccines like Pandemrix and Arepanrix enabled dose-sparing, allowing more than 90 million doses to be distributed worldwide despite limited antigen supply.

The COVID-19 crisis further underscored the value of adjuvants, with Novavax's Matrix-M-adjuvanted vaccine earning emergency approvals in multiple countries and demonstrating strong immunogenicity comparable to mRNA platforms. The same R21/MATRIX-M is also central to the R21 malaria vaccine, which recently achieved 77% efficacy (according to the NIH), setting a benchmark for next-generation prophylactic vaccines. Beyond commercial successes, public health organizations like CEPI and BARDA have prioritized adjuvants in their preparedness strategies, funding platforms that can be rapidly adapted to new pathogens.

Additionally, the increasing frequency of zoonotic spillovers such as SARS-CoV-2, avian influenza strains, and Ebola outbreaks keeps the spotlight on technologies that can shorten vaccine timelines. In this context, adjuvants offer clear advantages, they enhance antigen efficiency, provide cross-protective immunity, and extend the durability of protection, all of which are crucial in outbreak settings. Industry leaders like GSK, Novavax, and Dynavax are at the forefront. Taken together, these factors show that the constant threat of pandemics is no longer just a temporary driver but a structural catalyst for sustained investment, innovation, and growth in the vaccine adjuvants market.

Restraints-Safety concerns and reactogenicity risks are hampering the growth of the vaccine adjuvants market

Safety concerns and reactogenicity risks remain among the most significant restraints hampering the growth of the vaccine adjuvants market, as stakeholders struggle to balance the clear benefits of enhanced immunogenicity with the potential for higher rates of side effects. While adjuvants like alum have been used safely for decades, reports of rare but controversial conditions such as macrophagic myofasciitis have fueled lingering skepticism in some populations.

More advanced systems, including AS01 (used in GSK's Shingrix) and AS03 (used in pandemic influenza vaccines like Pandemrix), have set new efficacy benchmarks but also demonstrated increased rates of local and systemic reactions compared with traditional alum-based formulations. Grade 3 systemic reactions such as fatigue, myalgia, and fever were also significantly more common in adjuvanted arms, with relative risks sometimes up to three times higher than controls, though serious adverse events and deaths were extremely rare (

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Product Type
- 2.4. Snippet by Route of Administration
- 2.5. Snippet by Application
- 2.6. Snippet by End-User
- 2.7. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Threat of Emerging Infectious Diseases and Pandemics
 - 3.1.1.2. Expanding Focus on Geriatric and Immunocompromised Populations
 - 3.1.2. Restraints
 - 3.1.2.1. Safety Concerns and Reactogenicity Risks
 - 3.1.2.2. Limited Global Availability and Distribution Inequities
 - 3.1.3. Opportunity
 - 3.1.3.1. Integration with Next-Generation Vaccine Platforms
 - 3.1.3.2. Expanding Role in Cancer and Therapeutic Vaccines
 - 3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand
 - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs

- 4.3. Regulatory and Reimbursement Landscape
 - 4.3.1. North America
 - 4.3.2. Europe
 - 4.3.3. Asia Pacific
 - 4.3.4. South America
 - 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
- 4.5. Patent Analysis
- 4.6. Unmet Needs and Gaps
- 4.7. Recommended Strategies for Market Entry and Expansion
- 4.8. Pricing Analysis and Price Dynamics

5. VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 5.1.2. Market Attractiveness Index, By Product Type
- 5.2. Particulate Adjuvants*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Adjuvant Emulsions
- 5.4. Pathogen Components
- 5.5. Combination Adjuvants
- 5.6. Others

6. VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 6.1.2. Market Attractiveness Index, By Route of Administration
- 6.2. Intramuscular*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Oral
- 6.4. Intradermal
- 6.5. Subcutaneous
- 6.6. Intranasal

7. VACCINE ADJUVANTS MARKET, BY APPLICATION

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

7.1.2. Market Attractiveness Index, By Application

7.2. Infectious Diseases*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Cancer

7.4. Others

8. VACCINE ADJUVANTS MARKET, BY END-USER

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.1.2. Market Attractiveness Index, By End-User

8.2. Pharmaceutical and Biotech Companies*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Research Institutes

8.4. Others

9. BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.7.1. U.S.

9.2.7.2. Canada

9.2.7.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.7.1. Germany

9.3.7.2. UK

9.3.7.3. France

9.3.7.4. Spain

9.3.7.5. Italy

9.3.7.6. Rest of Europe

9.4. Asia-Pacific

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.7.1. China

9.4.7.2. India

9.4.7.3. Japan

9.4.7.4. South Korea

9.4.7.5. Rest of Asia-Pacific

9.5. South America

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.7.1. Brazil

9.5.7.2. Argentina

9.5.7.3. Rest of South America

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

10.1. Competitive Overview and Key Market Players

10.2. Market Share Analysis and Positioning Matrix

10.3. Strategic Partnerships, Mergers & Acquisitions

10.4. Key Developments in Product Portfolios and Innovations

10.5. Company Benchmarking

11. COMPANY PROFILES

11.1. GSK*

11.1.1. Company Overview

11.1.2. Product Portfolio

11.1.2.1. Product Description

11.1.2.2. Product Key Performance Indicators (KPIs)

11.1.3. Financial Overview

11.1.3.1. Company Revenue

11.1.3.2. Geographical Revenue Shares

11.1.3.3. Revenue Forecasts

11.1.4. Key Developments

11.1.4.1. Mergers & Acquisitions

11.1.4.2. Key Product Development Activities

11.1.4.3. Regulatory Approvals, etc.

11.1.4.4. SWOT Analysis

11.2. Dynavax Technologies

11.3. Novavax

11.4. SPI Pharma

11.5. Agenus Inc.

- 11.6. CSL
- 11.7. InvivoGen
- 11.8. Brenntag Nicaragua, S.A.
- 11.9. OZ Biosciences (LIST NOT EXHAUSTIVE)

12. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 12.1. Data Collection Methods
- 12.2. Data Triangulation
- 12.3. Forecasting Techniques
- 12.4. Data Verification and Validation

13. APPENDIX

- 13.1. About Us and Services
- 13.2. Contact Us

List Of Tables

LIST OF TABLES

- Table 1 Global Vaccine Adjuvants Market Value, By Product Type, 2025, 2029 & 2033 (US\$ Million)
- Table 2 Global Vaccine Adjuvants Market Value, By Route of Administration, 2025, 2029 & 2033 (US\$ Million)
- Table 3 Global Vaccine Adjuvants Market Value, By Application, 2025, 2029 & 2033 (US\$ Million)
- Table 4 Global Vaccine Adjuvants Market Value, By End-User, 2025, 2029 & 2033 (US\$ Million)
- Table 5 Global Vaccine Adjuvants Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)
- Table 6 Global Vaccine Adjuvants Market Value, By Product Type, 2025, 2029 & 2033 (US\$ Million)
- Table 7 Global Vaccine Adjuvants Market Value, By Product Type, 2022-2033 (US\$ Million)
- Table 8 Global Vaccine Adjuvants Market Value, By Route of Administration, 2025, 2029 & 2033 (US\$ Million)
- Table 9 Global Vaccine Adjuvants Market Value, By Route of Administration, 2022-2033 (US\$ Million)
- Table 10 Global Vaccine Adjuvants Market Value, By Application, 2025, 2029 & 2033 (US\$ Million)
- Table 11 Global Vaccine Adjuvants Market Value, By Application, 2022-2033 (US\$ Million)
- Table 12 Global Vaccine Adjuvants Market Value, By End-User, 2025, 2029 & 2033 (US\$ Million)
- Table 13 Global Vaccine Adjuvants Market Value, By End-User, 2022-2033 (US\$ Million)
- Table 14 Global Vaccine Adjuvants Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)
- Table 15 Global Vaccine Adjuvants Market Value, By Region, 2022-2033 (US\$ Million)
- Table 16 North America Vaccine Adjuvants Market Value, By Product Type, 2022-2033 (US\$ Million)
- Table 17 North America Vaccine Adjuvants Market Value, By Route of Administration, 2022-2033 (US\$ Million)
- Table 18 North America Vaccine Adjuvants Market Value, By Application, 2022-2033 (US\$ Million)

Table 19 North America Vaccine Adjuvants Market Value, By End-User, 2022-2033 (US\$ Million)

Table 20 North America Vaccine Adjuvants Market Value, By Country, 2022-2033 (US\$ Million)

Table 21 Europe Vaccine Adjuvants Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 22 Europe Vaccine Adjuvants Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 23 Europe Vaccine Adjuvants Market Value, By Application, 2022-2033 (US\$ Million)

Table 24 Europe Vaccine Adjuvants Market Value, By End-User, 2022-2033 (US\$ Million)

Table 25 Europe Vaccine Adjuvants Market Value, By Country, 2022-2033 (US\$ Million)

Table 26 Asia-Pacific Vaccine Adjuvants Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 27 Asia-Pacific Vaccine Adjuvants Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 28 Asia-Pacific Vaccine Adjuvants Market Value, By Application, 2022-2033 (US\$ Million)

Table 29 Asia-Pacific Vaccine Adjuvants Market Value, By End-User, 2022-2033 (US\$ Million)

Table 30 Asia-Pacific Vaccine Adjuvants Market Value, By Country, 2022-2033 (US\$ Million)

Table 31 South America Vaccine Adjuvants Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 32 South America Vaccine Adjuvants Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 33 South America Vaccine Adjuvants Market Value, By Application, 2022-2033 (US\$ Million)

Table 34 South America Vaccine Adjuvants Market Value, By End-User, 2022-2033 (US\$ Million)

Table 35 South America Vaccine Adjuvants Market Value, By Country, 2022-2033 (US\$ Million)

Table 36 Middle East and Africa Vaccine Adjuvants Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 37 Middle East and Africa Vaccine Adjuvants Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 38 Middle East and Africa Vaccine Adjuvants Market Value, By Application, 2022-2033 (US\$ Million)

Table 39 Middle East and Africa Vaccine Adjuvants Market Value, By End-User, 2022-2033 (US\$ Million)

Table 40 Middle East and Africa Vaccine Adjuvants Market Value, By Country, 2022-2033 (US\$ Million)

Table 41 GSK: Overview

Table 42 GSK: Product Portfolio

Table 43 GSK: Key Developments

Table 44 Dynavax Technologies: Overview

Table 45 Dynavax Technologies: Product Portfolio

Table 46 Dynavax Technologies: Key Developments

Table 47 Novavax: Overview

Table 48 Novavax: Product Portfolio

Table 49 Novavax: Key Developments

Table 50 SPI Pharma: Overview

Table 51 SPI Pharma: Product Portfolio

Table 52 SPI Pharma: Key Developments

Table 53 Agenus Inc.: Overview

Table 54 Agenus Inc.: Product Portfolio

Table 55 Agenus Inc.: Key Developments

Table 56 CSL: Overview

Table 57 CSL: Product Portfolio

Table 58 CSL: Key Developments

Table 59 InvivoGen: Overview

Table 60 InvivoGen: Product Portfolio

Table 61 InvivoGen: Key Developments

Table 62 Brenntag Nicaragua, S.A.: Overview

Table 63 Brenntag Nicaragua, S.A.: Product Portfolio

Table 64 Brenntag Nicaragua, S.A.: Key Developments

Table 65 OZ Biosciences: Overview

Table 66 OZ Biosciences: Product Portfolio

Table 67 OZ Biosciences: Key Developments

List Of Figures

LIST OF FIGURES

Figure 1 Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 2 Global Vaccine Adjuvants Market Share, By Product Type, 2024 & 2033 (%)

Figure 3 Global Vaccine Adjuvants Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 4 Global Vaccine Adjuvants Market Share, By Application, 2024 & 2033 (%)

Figure 5 Global Vaccine Adjuvants Market Share, By End-User, 2024 & 2033 (%)

Figure 6 Global Vaccine Adjuvants Market Share, By Region, 2024 & 2033 (%)

Figure 7 Global Vaccine Adjuvants Market Y-o-Y Growth, By Product Type, 2023-2033 (%)

Figure 8 Particulate Adjuvants Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 9 Adjuvant Emulsions Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 10 Pathogen Components Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 11 Combination Adjuvants Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 12 Others Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 13 Global Vaccine Adjuvants Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 14 Intramuscular Route of Administration in Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 15 Oral Route of Administration in Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 16 Intradermal Route of Administration in Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 17 Subcutaneous Route of Administration in Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 18 Intranasal Route of Administration in Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 19 Global Vaccine Adjuvants Market Y-o-Y Growth, By Application, 2023-2033 (%)

Figure 20 Infectious Diseases Application in Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 21 Cancer Application in Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 22 Others Application in Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 23 Global Vaccine Adjuvants Market Y-o-Y Growth, By End-User, 2023-2033 (%)

Figure 24 Pharmaceutical and Biotech Companies End-User in Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 25 Research Institutes End-User in Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 26 Others End-User in Global Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 27 Global Vaccine Adjuvants Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 28 North America Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 29 North America Vaccine Adjuvants Market Share, By Product Type, 2024 & 2033 (%)

Figure 30 North America Vaccine Adjuvants Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 31 North America Vaccine Adjuvants Market Share, By Application, 2024 & 2033 (%)

Figure 32 North America Vaccine Adjuvants Market Share, By End-User, 2024 & 2033 (%)

Figure 33 North America Vaccine Adjuvants Market Share, By Country, 2024 & 2033 (%)

Figure 34 Europe Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 35 Europe Vaccine Adjuvants Market Share, By Product Type, 2024 & 2033 (%)

Figure 36 Europe Vaccine Adjuvants Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 37 Europe Vaccine Adjuvants Market Share, By Application, 2024 & 2033 (%)

Figure 38 Europe Vaccine Adjuvants Market Share, By End-User, 2024 & 2033 (%)

Figure 39 Europe Vaccine Adjuvants Market Share, By Country, 2024 & 2033 (%)

Figure 40 Asia-Pacific Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 41 Asia-Pacific Vaccine Adjuvants Market Share, By Product Type, 2024 & 2033 (%)

Figure 42 Asia-Pacific Vaccine Adjuvants Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 43 Asia-Pacific Vaccine Adjuvants Market Share, By Application, 2024 & 2033 (%)

Figure 44 Asia-Pacific Vaccine Adjuvants Market Share, By End-User, 2024 & 2033 (%)

Figure 45 Asia-Pacific Vaccine Adjuvants Market Share, By Country, 2024 & 2033 (%)

Figure 46 South America Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 47 South America Vaccine Adjuvants Market Share, By Product Type, 2024 &

2033 (%)

Figure 48 South America Vaccine Adjuvants Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 49 South America Vaccine Adjuvants Market Share, By Application, 2024 & 2033 (%)

Figure 50 South America Vaccine Adjuvants Market Share, By End-User, 2024 & 2033 (%)

Figure 51 South America Vaccine Adjuvants Market Share, By Country, 2024 & 2033 (%)

Figure 52 Middle East and Africa Vaccine Adjuvants Market Value, 2022-2033 (US\$ Million)

Figure 53 Middle East and Africa Vaccine Adjuvants Market Share, By Product Type, 2024 & 2033 (%)

Figure 54 Middle East and Africa Vaccine Adjuvants Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 55 Middle East and Africa Vaccine Adjuvants Market Share, By Application, 2024 & 2033 (%)

Figure 56 Middle East and Africa Vaccine Adjuvants Market Share, By End-User, 2024 & 2033 (%)

Figure 57 GSK: Financials

Figure 58 Dynavax Technologies: Financials

Figure 59 Novavax: Financials

Figure 60 SPI Pharma: Financials

Figure 61 Agenesis Inc.: Financials

Figure 62 CSL: Financials

Figure 63 InvivoGen: Financials

Figure 64 Brenntag Nicaragua, S.A.: Financials

Figure 65 OZ Biosciences: Financials

I would like to order

Product name: Global Vaccine Adjuvants Market - 2025 -2033

Product link: <https://marketpublishers.com/r/G0848AFC1466EN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0848AFC1466EN.html>